--- canonical_name: Melanotan II alternate_names: MT-II, MT-2, Melanotan 2, MTII, Melanotan-II, cyclic α-MSH analog canonical_topic: Melanotan II for Health & Longevity short_topic_lc: melanotan_ii creation_date: 2026-0701-0217 creator_ai_fullname: Opus 4.8 --- # Melanotan II for Health & Longevity
Evidence Review created on 07/01/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** MT-II, MT-2, Melanotan 2, MTII, Melanotan-II, cyclic α-MSH analog ## Motivation Melanotan II (also called MT-II) is a lab-made peptide, a small chain of amino acids, that mimics a natural hormone the body uses to darken the skin. Injected under the skin, it drives the skin to make more of its dark pigment, producing a tan with little or no sun exposure. Beyond tanning, the same peptide acts on the brain, where it can raise sexual desire and trigger erections, and it tends to blunt appetite. This mix of pigment, sexual, and appetite effects is why it draws interest well outside cosmetic tanning. The peptide grew out of university research in the 1980s aimed at protecting fair-skinned people from sun damage by boosting their natural pigment. It never became an approved medicine in this form, yet it is widely sold online and through gyms as an unregulated grey-market product, and it has been flagged by health regulators in several countries because of safety concerns. This review examines what the evidence shows about Melanotan II, including how it works, the effects people seek from it, the documented risks such as changing moles and cardiovascular events, and the quality-control problems that come with an unlicensed injectable peptide. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-quality, high-level overviews of Melanotan II from experts and primary sources that discuss the peptide by name and in depth. * [AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field](https://peterattiamd.com/ama83/) - Peter Attia A physician-led deep dive into grey-market peptides that treats Melanotan II as a case study, weighing its claimed effects against its safety profile and the problems of unregulated sourcing. * [Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review](https://pubmed.ncbi.nlm.nih.gov/28266027/) - Habbema et al., 2017 A narrative review covering the history, the approved analog afamelanotide, and the documented cutaneous complications of grey-market melanotan use, including changing moles and reported melanomas. * [Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction](https://pubmed.ncbi.nlm.nih.gov/11018622/) - Wessells et al., 2000 A foundational human study documenting the erection- and desire-enhancing effects that underlie much of the non-cosmetic interest in the peptide, from the research group that pioneered its clinical testing. *Note: Fewer than five sources are listed to avoid padding with marginal content. Of the priority experts, only Peter Attia returned directly relevant, stably accessible coverage; Andrew Huberman's platform discusses melanotan peptides but its clip pages are access-gated and could not be linked reliably, and Rhonda Patrick, Chris Kresser, and Life Extension Magazine returned no substantive Melanotan II coverage.* ## Grokipedia * [Melanotan II](https://grokipedia.com/page/Melanotan_II) - Grokipedia A comprehensive reference entry covering the peptide's pharmacology, history, cosmetic and sexual uses, and the documented safety concerns and regulatory status. ## Examine No Examine article exists for Melanotan II. Examine.com focuses on dietary supplements with human evidence and does not cover unapproved injectable peptides such as this one. ## ConsumerLab No ConsumerLab article exists for Melanotan II. ConsumerLab tests commercially available dietary supplements and does not cover unapproved injectable peptides sold through grey-market channels. ## Systematic Reviews No systematic reviews or meta-analyses for Melanotan II were found on PubMed as of 07/01/2026. ## Mechanism of Action Melanotan II is a synthetic cyclic peptide modeled on alpha-melanocyte-stimulating hormone (α-MSH, a natural hormone that signals skin cells to make pigment). It is a broad, non-selective agonist (activator) of the melanocortin receptors, binding MC1R, MC3R, MC4R, and MC5R, while sparing the adrenal MC2R. The primary mechanisms are: * **Pigmentation (MC1R):** Activating MC1R on melanocytes (pigment-producing skin cells) shifts them toward producing eumelanin, the darker, more photoprotective pigment. This drives skin darkening independent of ultraviolet exposure, though some pigment response is amplified by sunlight. * **Sexual function (MC4R, MC3R):** Activating MC4R and MC3R in the hypothalamus and spinal cord stimulates central nervous system pathways that increase sexual desire and initiate erections. This is a brain-mediated effect, distinct from the vascular action of drugs like sildenafil. * **Appetite and energy balance (MC4R):** MC4R signaling in the hypothalamus suppresses appetite. This is the same pathway targeted therapeutically by setmelanotide for genetic obesity, and it explains the reduced appetite many users report. Because Melanotan II crosses the blood-brain barrier and hits multiple receptors at once, its effects are not confined to skin; the same dose that tans also acts on sexual, appetite, and cardiovascular control centers. Competing mechanistic views exist on the melanoma question. One view holds that stimulating melanocyte activity and driving proliferation of pigmented lesions could promote malignant transformation; the opposing view notes that eumelanin is photoprotective and that no causal human mechanism has been established, leaving the observed melanoma case reports unexplained by a proven pathway. **Key pharmacological properties:** Melanotan II is a peptide administered by subcutaneous injection (not orally active, as it would be digested). Reported plasma half-life is short, on the order of roughly 1–2 hours, but its biological pigmentary effect persists for days because melanin synthesis is downstream and long-lived. As a peptide, it is cleared by peptidase breakdown rather than by liver cytochrome P450 enzymes, so classic CYP-based drug interactions are not the main concern. Selectivity is deliberately broad (non-selective across MC1/3/4/5R), which is central to both its multi-system effects and its off-target risks. ## Historical Context & Evolution * **Original intended use:** Melanotan II descends from work at the University of Arizona in the 1980s, where researchers sought a "sunless tanning" agent that would raise the skin's own protective pigment to reduce skin-cancer risk in fair-skinned people. The parent molecule was α-MSH; medicinal chemistry produced the more potent, longer-acting cyclic analog now known as Melanotan II. * **Why it came to be considered for optimization:** During early human testing, investigators observed that the peptide produced spontaneous erections and heightened sexual desire. This unexpected finding split the development path: the erectile effect was pursued as a separate drug (bremelanotide, later approved as a treatment for low sexual desire in women), while the pigmentary agent was pursued for photoprotection. * **What the historical research actually found:** Early controlled human studies confirmed both dose-dependent tanning and central sexual effects. The Wessells group documented erections and increased desire in men. These were genuine pharmacological findings, not artifacts, and they are the foundation of the peptide's continued grey-market appeal. * **Evolution of standing:** The original tanning compound was never approved in this exact form. A closely related, more selective analog, afamelanotide (marketed as SCENESSE), was developed and later approved to prevent phototoxic reactions in erythropoietic protoporphyria, a rare light-sensitivity disorder. Melanotan II itself moved into an unregulated grey market, where it is sold as "the Barbie drug" for tanning and libido. What changed over time was not the pharmacology but the regulatory and safety picture: accumulating case reports of changing moles, melanoma, priapism, and cardiovascular and kidney events prompted health-authority warnings in multiple countries, while the approval of afamelanotide showed that a carefully controlled melanocortin agonist can be used safely in a defined medical setting. ## Expected Benefits The effects below are framed for a proactive, risk-aware adult evaluating the peptide, not as population-level recommendations. ### High 🟩 🟩 🟩 #### Skin Tanning (Increased Melanization) Melanotan II reliably darkens the skin by driving eumelanin production through MC1R activation, producing a tan with minimal or no ultraviolet exposure. This is the most consistently observed and reproducible effect across early controlled human studies and extensive grey-market user experience. The effect is dose-dependent and develops over days to weeks; it is often amplified by some sun exposure. Limitations: response varies by baseline skin type, and the cosmetic benefit is inseparable from the pigmentary risks (mole changes) discussed in the Risks section. **Magnitude:** Visible, dose-dependent skin darkening within 1–3 weeks of regular dosing; the tan fades over weeks after discontinuation as pigmented cells turn over. ### Medium 🟩 🟩 #### Erectile Function and Sexual Desire By activating MC4R and MC3R in the brain and spinal cord, Melanotan II can initiate erections and raise sexual desire in both men and women through a central mechanism distinct from blood-flow drugs. The controlled human evidence is limited but real: small placebo-controlled crossover studies (Wessells and colleagues) showed erections and increased desire in men with erectile dysfunction. The strength of this evidence is capped by small sample sizes and the fact that the more rigorously developed, receptor-selective successor (bremelanotide) is what advanced to approval. Nausea and yawning frequently accompany the sexual response. **Magnitude:** In small crossover studies, roughly a majority of dosed men achieved clinically meaningful erections versus few on placebo; effect onset within 1–3 hours of injection. ### Low 🟩 #### Appetite Suppression and Modest Fat Loss Through MC4R signaling in the hypothalamus, Melanotan II tends to reduce appetite, and some users report modest weight loss. The mechanism is well established (the same pathway is targeted by the approved obesity drug setmelanotide), but direct controlled human weight-loss data for Melanotan II specifically are sparse and mostly anecdotal or from early metabolic studies. This is best regarded as a real but poorly quantified side effect that some users pursue deliberately. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Anti-Inflammatory and Cytoprotective Effects The melanocortin system has documented anti-inflammatory and tissue-protective roles, and melanocortin peptides are being explored for inflammatory eye and other conditions. Whether Melanotan II delivers meaningful anti-inflammatory or longevity-relevant protection in healthy humans is unproven; the basis is mechanistic and preclinical only, with no controlled human outcome data supporting a longevity benefit. ## Benefit-Modifying Factors * **MC1R genetic variants:** People carrying loss-of-function MC1R variants (common in red-haired, very fair-skinned individuals) have a blunted pigmentary response, since the receptor that drives tanning is less functional. These same individuals also carry higher baseline melanoma risk, compounding concern. * **Baseline skin type and pigment:** Darker baseline skin types tend to tan more readily and visibly; very fair individuals may need higher or more frequent dosing to achieve the same cosmetic effect, increasing systemic exposure. * **Sex-based differences:** The sexual-response effects manifest differently by sex (erections in men; desire and genital arousal changes in women). Appetite and pigmentary effects are broadly similar across sexes. * **Pre-existing pigmented lesions:** Individuals with many moles or atypical (dysplastic) nevi may see more pronounced darkening and enlargement of existing lesions, which is cosmetically undesirable and clinically concerning. * **Age-related considerations:** Older adults, including those at the upper end of the target range, carry higher baseline cardiovascular and cutaneous-malignancy risk, so the risk-adjusted value of any cosmetic or sexual benefit is lower for them than for younger users. ## Potential Risks & Side Effects Risks are framed for a proactive adult who might self-administer this peptide, not as population averages. ### High 🟥 🟥 🟥 #### Changing Moles and Melanoma Concern Melanotan II darkens and can enlarge existing moles and drive the appearance of new pigmented lesions (nevi), a consistently reported effect tied directly to melanocyte stimulation. Multiple published case reports describe melanoma arising during or shortly after use. Causation is not proven, and the darkening can also mask early cancer signs and delay diagnosis. The evidence basis is numerous dermatology case reports and reviews; severity is high because melanoma is potentially fatal, and the change is not readily reversible. **Magnitude:** Multiple independent case reports of melanoma temporally associated with use; near-universal reports of mole darkening/enlargement among regular users. #### Nausea and Facial Flushing Nausea, often with facial flushing, is among the most common acute effects, typically occurring shortly after injection due to central melanocortin activation. It is dose-related and usually transient but frequent enough to be a defining feature of the experience. Evidence basis: early clinical studies and extensive user reports. Severity is usually mild to moderate and reversible, but it is very common. **Magnitude:** Reported by a large proportion of users, often within 1–2 hours of dosing. ### Medium 🟥 🟥 #### Priapism (Prolonged, Painful Erection) Because the peptide activates central erectile pathways, it can cause priapism, an erection lasting hours that is a urological emergency. Published case reports describe low-flow priapism requiring aspiration, irrigation, and injected phenylephrine, with incomplete recovery of erectile function at follow-up. Evidence basis: emergency-medicine and urology case reports. Severity can be high (risk of permanent erectile damage), though the event is uncommon relative to milder sexual effects. **Magnitude:** Rare but documented; individual cases required emergency intervention and left lasting dysfunction. #### Cardiovascular and Renal Events Non-selective melanocortin activation can raise blood pressure and has been linked in case reports to serious vascular events, including rhabdomyolysis (muscle breakdown) with kidney injury and renal infarction (blocked blood flow to the kidney), a potentially life-threatening condition. The proposed mechanism involves pressor and possible thrombotic or direct toxic effects. Evidence basis: individual case reports and reviews. Severity is high when it occurs, though frequency appears low. **Magnitude:** Not quantified in available studies. ### Low 🟥 #### Yawning, Appetite Loss, and Fatigue Compulsive yawning and stretching, reduced appetite, and fatigue are frequently reported and stem from central melanocortin effects and blood-brain-barrier penetration. These are generally mild and reversible but can be pronounced enough to disrupt daily activity. Evidence basis: clinical studies and user reports. **Magnitude:** Commonly reported; generally mild and transient. ### Speculative 🟨 #### Injection-Site Infections and Blood-Borne Disease Because the product is a self-injected, unregulated peptide, non-sterile technique or shared needles can cause skin infections, abscesses, or transmission of blood-borne viruses. This risk is a function of unregulated grey-market use rather than the molecule itself; its magnitude depends entirely on user practice and product quality, and no systematic data quantify it. ## Risk-Modifying Factors * **MC1R and melanoma-risk genetics:** Individuals with MC1R loss-of-function variants and a family or personal history of melanoma face a higher-stakes risk profile if pigmented lesions change under the peptide. * **Baseline cardiovascular status:** Pre-existing hypertension or vascular disease raises the danger of the peptide's pressor and thrombotic-associated events (renal infarction, rhabdomyolysis). * **Sex-based differences:** Men bear the specific risk of priapism; both sexes share the pigmentary and cardiovascular risks. * **Pre-existing pigmented-lesion burden:** A high count of atypical moles increases the likelihood of clinically significant changes and diagnostic confusion. * **Age-related considerations:** Older users, including those at the older end of the target range, have higher baseline cardiovascular and skin-cancer risk, amplifying the consequences of any adverse event. ## Key Interactions & Contraindications * **Prescription drug interactions:** Combining with other sexual-function agents such as PDE5 inhibitors (drugs that improve erections by increasing blood flow to the penis; sildenafil, tadalafil) can compound the risk of priapism; concurrent stimulants or vasopressors may add to blood-pressure elevation. Severity: caution to potential contraindication; consequence: prolonged erection, hypertension. * **Over-the-counter medications:** OTC decongestants and stimulants containing sympathomimetics (pseudoephedrine, phenylephrine) may additively raise blood pressure. Severity: caution; consequence: hypertension. * **Supplement interactions:** Stimulant "fat burner" supplements (caffeine, synephrine, yohimbine) may compound cardiovascular and appetite effects. Severity: caution; consequence: elevated blood pressure, tachycardia. * **Additive-effect supplements:** Other appetite-suppressing or libido-enhancing agents (e.g., yohimbine, which also acts on sexual pathways) can potentiate both the intended sexual effect and the cardiovascular strain. * **Other intervention interactions:** Concurrent ultraviolet tanning (sunbeds, sun exposure) synergizes with the pigmentary effect and simultaneously increases DNA-damage and melanoma risk to skin and moles. * **Populations who should avoid it:** People with a personal or strong family history of melanoma or many atypical moles; individuals with uncontrolled hypertension or established cardiovascular or cerebrovascular disease; those with prior priapism or sickle-cell disease (priapism-prone); pregnant or breastfeeding individuals (no safety data); and anyone unable to ensure sterile injection technique and product quality. * **Population thresholds:** Absolute caution applies to uncontrolled hypertension (e.g., resting BP consistently >160/100 mmHg), any prior priapism episode, and known personal history of invasive melanoma. If a mitigating action is known, it is to obtain a full-body skin examination before and periodically during use and to avoid combining with other pro-erectile or pressor agents. ## Risk Mitigation Strategies * **Baseline and periodic dermatology screening:** Because the highest-stakes risk is melanoma and masked mole changes, a full-body skin examination by a dermatologist before starting and at regular intervals (e.g., every 6–12 months) allows early detection; photograph moles to track change and reduce diagnostic delay. * **Cardiovascular baseline and monitoring:** To mitigate the pressor and vascular event risk, measure blood pressure before starting and periodically thereafter; avoid use with uncontrolled hypertension and discontinue if blood pressure rises persistently. * **Sterile single-use injection technique:** To mitigate injection-site infection and blood-borne disease, use only new, sterile, single-use needles and syringes, never share equipment, and use aseptic reconstitution and injection practice. * **Conservative dosing and slow titration:** To reduce the frequency of nausea, flushing, and priapism, users typically start with a low test dose and increase slowly; lower cumulative exposure reduces both acute effects and systemic strain. * **Avoid combining with pro-erectile or stimulant agents:** To prevent priapism and additive hypertension, separate Melanotan II from PDE5 inhibitors, sympathomimetic decongestants, and stimulant supplements. * **Have a priapism action plan:** Because a prolonged erection is a urological emergency, users should know that an erection lasting more than roughly 4 hours requires immediate medical care to prevent permanent damage. ## Therapeutic Protocol Melanotan II is not an approved medicine in this form, so no official protocol exists; the following describes patterns reported by grey-market users and discussed by practitioners, presented without endorsement. * **Standard grey-market approach:** A "loading" phase of small daily subcutaneous injections until the desired tan develops, followed by a lower-frequency "maintenance" phase (e.g., one or two injections per week) to sustain pigmentation. This is the most commonly described pattern, not a validated regimen. * **Competing approaches:** Some users pursue tanning alone with minimal sun exposure; others deliberately combine low-dose peptide with limited ultraviolet exposure to accelerate and deepen the tan. The two approaches trade cosmetic speed against added ultraviolet risk; neither is framed here as the default. * **Popularized by:** The tanning application spread largely through online communities and gym culture rather than a named clinic; the sexual-function application traces to the University of Arizona research group (Wessells, Hadley, Dorr and colleagues). * **Best time of day:** Many users inject in the evening because the common side effects (nausea, flushing, fatigue, spontaneous erection) are then less disruptive and can coincide with sleep. * **Half-life consideration:** The plasma half-life is short (roughly 1–2 hours), but the pigmentary effect is long-lived because it depends on melanin already produced; this is why maintenance dosing can be infrequent even though the peptide itself clears quickly. * **Single vs. split dosing:** Because the acute side effects are dose-related, users often favor smaller, more frequent doses over large single doses to improve tolerability. * **Genetic considerations:** MC1R variant carriers (very fair, red-haired individuals) respond poorly to the pigmentary effect and may be tempted toward higher doses, raising systemic exposure and risk; this is a reason for caution rather than dose escalation. * **Sex-based differences:** Dosing patterns are similar across sexes, but the sexual-response profile differs (erections in men, desire and arousal changes in women), and men must weigh priapism risk. * **Age-related considerations:** Older users, including those at the older end of the target range, should weigh the elevated cardiovascular and skin-cancer stakes against a purely cosmetic or lifestyle benefit. * **Baseline biomarkers:** Blood pressure and a documented skin/mole baseline are the practical pre-use measures most relevant to safe use. * **Pre-existing conditions:** Hypertension, cardiovascular disease, prior priapism, and a heavy or atypical mole burden all argue against use or for heightened caution. ## Discontinuation & Cycling * **Lifelong vs. short-term:** Melanotan II is used episodically, not as a lifelong therapy; there is no medical indication for chronic use in healthy people, and the tan fades after stopping. * **Withdrawal effects:** No classic physical withdrawal syndrome is described; the main "withdrawal" is the gradual loss of tan as pigmented skin cells turn over. * **Tapering:** Formal tapering is not required pharmacologically; users simply stop, after which pigmentation fades over weeks. * **Cycling:** Because of the accumulating pigmentary risk (mole changes) and systemic effects, the safest pattern is limited, infrequent use with breaks rather than continuous dosing; cycling is not needed to maintain efficacy but is prudent to limit cumulative exposure and allow dermatologic surveillance. ## Sourcing and Quality * **Unregulated supply:** Melanotan II is sold almost entirely through the grey market (online vendors, gyms) without pharmaceutical oversight, so purity, dose accuracy, and sterility are not guaranteed. This is the single largest quality concern. * **What to look for:** In the absence of regulation, buyers seek vials with third-party analytical certificates of analysis (identity and purity testing), sealed lyophilized (freeze-dried) powder rather than pre-mixed solution, and reconstitution with sterile bacteriostatic water. None of this substitutes for approved-drug quality control. * **Reputable options:** There is no legitimately approved consumer source for Melanotan II in this form. The only approved, quality-controlled melanocortin analog for skin use is afamelanotide (SCENESSE), available by prescription for a specific rare disorder, not for cosmetic tanning. Users should understand that any tanning-peptide vendor operates outside pharmaceutical regulation. ## Practical Considerations * **Time to effect:** Visible tanning typically develops over 1–3 weeks of regular dosing; sexual effects can appear within 1–3 hours of a single injection. * **Common pitfalls:** Overdosing to speed tanning (worsening nausea, flushing, and priapism risk), ignoring changing moles, combining with sunbeds or pro-erectile drugs, and using non-sterile injection technique are the most frequent and consequential mistakes. * **Regulatory status:** Melanotan II is not approved for any use in the United States, the United Kingdom, Australia, or the European Union, and health regulators in multiple countries have issued warnings against it; it is nonetheless widely sold online. Its approved relative, afamelanotide, is prescription-only for erythropoietic protoporphyria. * **Cost and accessibility:** The peptide itself is inexpensive and easy to obtain online, which paradoxically raises risk by lowering the barrier to unsupervised, unregulated use. ## Interaction with Foundational Habits * **Sleep:** Direct effect. Central melanocortin activation and blood-brain-barrier penetration can cause fatigue and pronounced yawning; some users report drowsiness after dosing, which is one reason evening injection is common. Spontaneous nighttime erections can also disrupt sleep. * **Nutrition:** Direct, blunting effect on intake. MC4R-mediated appetite suppression reduces hunger, which some users welcome and others find leads to under-eating; there is no specific food to pair it with, but adequate nutrition should be maintained despite reduced appetite. * **Exercise:** Indirect interaction. There is no evidence it enhances training, but appetite suppression and fatigue could impair fueling and recovery; the blood-pressure-raising effect argues for caution around high-intensity exercise in anyone with cardiovascular risk. * **Stress management:** Indirect. The melanocortin system intersects with stress-hormone (cortisol) pathways centrally, but Melanotan II largely spares the adrenal MC2R, so a direct cortisol surge is not expected; the acute side effects (nausea, flushing) can themselves be a stressor, and managing dosing to minimize them improves tolerability. ## Monitoring Protocol & Defining Success Because the dominant risks are cutaneous and cardiovascular, monitoring centers on skin surveillance and blood pressure. A full-body skin examination and blood-pressure check should be performed before starting. Ongoing monitoring: repeat blood pressure at 1–2 weeks after initiation and periodically thereafter; perform dermatologic skin checks every 6–12 months (sooner if any mole changes), with baseline mole photography to detect change. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --- | --- | --- | --- | | Blood pressure | <120/80 mmHg | Peptide can raise blood pressure; screens for pressor effect | Measure seated, rested; recheck after dosing changes; conventional "normal" is <130/80 but functional target is tighter | | Full-body skin / mole mapping | No new or changing atypical lesions | Detects mole darkening, enlargement, or new nevi that could mask or signal melanoma | Photograph moles at baseline; dermatologist review; the peptide's pigment effect can obscure early cancer signs | | Resting heart rate | 50–70 bpm | Screens for cardiovascular strain alongside blood pressure | Best measured at rest; rising trend warrants reassessment | | Renal function (creatinine, eGFR) | eGFR >90 mL/min/1.73 m² | Screens for the rare renal infarction/rhabdomyolysis risk | eGFR estimates kidney filtration; check if flank pain, dark urine, or muscle pain occur; fasting not required | Qualitative markers to track: * Appearance, darkening, or enlargement of any mole (report promptly) * Energy levels and unusual fatigue * Appetite changes and unintended weight loss * Any erection lasting beyond a few hours (urological emergency) * Nausea and flushing severity as a tolerability guide ## Emerging Research The active research frontier for melanocortin agonists lies mostly with more selective, regulated successors rather than Melanotan II itself, from directions that both strengthen and weaken the case for the raw peptide. * **Bremelanotide/tirzepatide obesity trial:** [NCT06565611](https://clinicaltrials.gov/study/NCT06565611) — a Phase 2 study (Palatin Technologies, ~108 participants) co-administering the melanocortin agonist bremelanotide with tirzepatide for obesity, probing whether melanocortin activation adds to weight loss. Relevant because it tests the appetite pathway shared with Melanotan II in a controlled, regulated setting. * **Melanotan II for vitiligo repigmentation:** [NCT07437560](https://clinicaltrials.gov/study/NCT07437560) — a Phase 2 recruiting trial (~60 participants) testing Melanotan II itself as an add-on to narrow-band ultraviolet phototherapy for stable non-segmental vitiligo, one of the few registered studies of the actual peptide in a medical indication. * **Afamelanotide plus phototherapy for vitiligo:** [NCT06109649](https://clinicaltrials.gov/study/NCT06109649) — a Phase 3 study (Clinuvel, ~200 participants) comparing the approved analog SCENESSE plus narrow-band ultraviolet against ultraviolet alone, informing how a regulated melanocortin agonist performs where Melanotan II is used off-label. * **Melanoma-risk direction:** Future work that could weaken the case includes systematic follow-up of the published melanoma case reports ([Paurobally et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21564053/); [Habbema et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28266027/)); establishing or refuting a causal link would materially change the risk assessment. * **Cardiovascular/renal safety direction:** Structured pharmacovigilance of vascular events such as renal infarction and rhabdomyolysis ([Peters et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31953620/)) could clarify how common these rare but serious outcomes truly are. ## Conclusion Melanotan II is a lab-made peptide that copies a natural pigment hormone and, given by injection, darkens the skin without the sun while also acting on the brain to raise sexual desire, trigger erections, and blunt appetite. Its tanning and sexual effects are real and have been seen in early human studies, which is why it retains a following despite never being approved as a medicine in this form. The evidence base, however, is thin and dominated by small studies and individual case reports rather than large, high-quality trials, so confidence in its benefits is modest and confidence in the full scope of its harms is incomplete. The risks are the heart of the story. The peptide darkens and enlarges moles and can spur new ones, and several reports describe skin cancer appearing during or soon after use; the pigment change can also hide early warning signs. Prolonged painful erections, raised blood pressure, and rare but dangerous muscle and kidney events have all been reported, and because the product is sold outside any regulation, purity and sterility cannot be assumed. A carefully controlled relative is approved for a rare light-sensitivity condition, showing this class can be used safely in a defined setting, but that says little about unsupervised cosmetic use. For a health-focused adult, the documented and potentially serious harms weigh heavily against a mostly cosmetic reward. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**